Clinical Trial Update: SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes SELECT-SLE, a Phase 1/2 study of biomarker-guided CAR-T target selection for refractory systemic lupus erythematosus and lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Biomarker-guided CAR-T therapy (SELECT-SLE target selection)

Snippet

Sponsor: Beijing Biotech | Conditions: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | Phase 1, Phase 2 | Status: RECRUITING